Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-36333
Titel: | Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial |
VerfasserIn: | Böhm, Michael Slawik, Jonathan Brueckmann, Martina Mattheus, Michaela George, Jyothis T Ofstad, Anne Pernille Inzucchi, Silvio E Fitchett, David Anker, Stefan D Marx, Nikolaus Wanner, Christoph Zinman, Bernard Verma, Subodh |
Sprache: | Englisch |
Titel: | European Journal of Heart Failure |
Bandnummer: | 22 |
Heft: | 1 |
Seiten: | 126-135 |
Verlag/Plattform: | Wiley |
Erscheinungsjahr: | 2019 |
Freie Schlagwörter: | Diabetes Empagliflozin Heart failure Mortality Oedema SGLT2 inhibitors |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Aims Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA-REG OUTCOME trial explores CV and renal outcomes in patients with vs. without AF at baseline and assesses the benefits of empagliflozin. Methods and results Analyses were conducted on patients distinguished by the presence (n = 389) or absence (n = 6631) of AF at baseline. Outcome events were more frequent in patients with AF than those without AF. Empagliflozin compared to placebo reduced CV death or HF hospitalisation consistently in patients with AF [hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.36–0.92] and without AF (HR 0.67, 95% CI 0.55–0.82, Pinteraction = 0.56). Similar results were observed for the components of this endpoint, all-cause mortality, new or worsening nephropathy, first introduction of loop diuretics, or occurrence of oedema. The absolute number of prevented events was higher in patients with AF, resulting in larger absolute treatment effects of empagliflozin. New loop diuretics or oedema were associated with increased rates of subsequent events, and rates appeared lower in those randomised to empagliflozin. Conclusions In patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF-related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin. |
DOI der Erstveröffentlichung: | 10.1002/ejhf.1663 |
URL der Erstveröffentlichung: | https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1663 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-363331 hdl:20.500.11880/32999 http://dx.doi.org/10.22028/D291-36333 |
ISSN: | 1879-0844 1388-9842 |
Datum des Eintrags: | 2-Jun-2022 |
Bezeichnung des in Beziehung stehenden Objekts: | Supporting Information |
In Beziehung stehendes Objekt: | https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fejhf.1663&file=ejhf1663-sup-0001-TableS1.docx |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Innere Medizin |
Professur: | M - Prof. Dr. Michael Böhm |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.